ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

The Company is constructing its new European humanCEF in Geleen to increase the manufacturing capacity ofChondroCelect in Europe through TiGenix B.V.On November 30, 2009, the Company acquired OrthomimeticsLimited. Orthomimetics Limited designs, develops andmanufactures novel, bioresorbable implants for theregenerative repair of articular joint damage resulting fromsports injuries and other trauma. Orthomimetics Limited hasbeen renamed to TiGenix Ltd.On July 8, 2010, the Company has spun off drug discoveryassets to the Dutch company Arcarios B.V. (formerly namedTherosteon B.V.) in which the Company holds a 13.86% equitystake.On the Contribution Date, the Company acquired Cellerix.Cellerix is a Spanish cell therapy company that was foundedin 2004 as a spin-off from the Genetrix Group. Cellerix has aclinical stage pipeline of cell-based products for indicationsof inflammatory and autoimmune origin. Further details onCellerix are provided in section 6.14 of the prospectus.TiGenix NV100% 100% 100% 13.86% 100%TiGenix Inc.TiGenix B.V.TiGenix Ltd.Arcarios B.V.Cellerix S.A.4.4 Share capital and shares4.4.1 Share capital and SharesOn the date of publication of this prospectus, the Company’sregistered capital amounts to €74,243,046.23, represented by75,935,556 common Shares without nominal value. The capitalis fully paid up.The table below provides an overview of the history of theCompany’s share capital since its incorporation in 2000. Theoverview should be read together with the notes set outbelow the table.77 •